World's Best Scientists 2026 revealed!

D-Index & Metrics

Chemistry

D-Index
45
Citations
7332
World Ranking
16455
National Ranking
41

Brian D. Palmer publication distribution in Chemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Chemistry in 2026. The highlighted bar marks where Brian D. Palmer sits on this spectrum.

61–80 publications: 66 scientists 81–100 publications: 302 scientists 101–120 publications: 623 scientists 121–140 publications: 918 scientists 141–160 publications: 1,218 scientists 161–180 publications: 1,350 scientists 181–200 publications: 1,344 scientists 201–220 publications: 1,281 scientists 221–240 publications: 1,216 scientists 241–260 publications: 1,100 scientists 261–280 publications: 979 scientists 281–300 publications: 939 scientists 301–320 publications: 764 scientists 321–340 publications: 644 scientists 341–360 publications: 628 scientists 361–380 publications: 522 scientists 381–400 publications: 459 scientists 401–420 publications: 397 scientists 421–440 publications: 327 scientists 441–460 publications: 270 scientists 461–480 publications: 265 scientists 481–500 publications: 253 scientists 501–520 publications: 201 scientists 521–540 publications: 185 scientists 541–560 publications: 148 scientists 561–580 publications: 148 scientists 581–600 publications: 132 scientists 601–620 publications: 114 scientists 621–640 publications: 104 scientists 641–660 publications: 91 scientists 661–680 publications: 92 scientists 681–700 publications: 73 scientists 701–720 publications: 57 scientists 721–740 publications: 54 scientists 741–760 publications: 67 scientists 761–780 publications: 45 scientists 781–800 publications: 46 scientists 801–820 publications: 39 scientists 821–840 publications: 32 scientists 841–860 publications: 36 scientists 861–880 publications: 29 scientists 881–900 publications: 26 scientists 901–920 publications: 24 scientists 921–940 publications: 14 scientists 941–960 publications: 23 scientists 961–980 publications: 28 scientists 981–1,000 publications: 15 scientists 1,001–1,020 publications: 29 scientists 1,021–1,040 publications: 12 scientists 1,041–1,060 publications: 19 scientists 1,061–1,080 publications: 12 scientists 1,081–1,100 publications: 6 scientists 1,101–1,120 publications: 8 scientists 1,121–1,140 publications: 12 scientists 1,141–1,160 publications: 5 scientists 1,161–1,180 publications: 6 scientists 1,181–1,200 publications: 14 scientists 1,201–1,220 publications: 7 scientists 1,221–1,240 publications: 2 scientists 1,241–1,260 publications: 6 scientists 1,261–1,280 publications: 4 scientists 1,281–1,294 publications: 6 scientists 1,295+ publications: 100 scientists
61 publications 1,295+

This scientist: 136 publications — 9th percentile

9% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,295 publications or more.

Brian D. Palmer D-index placement in Chemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Chemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Brian D. Palmer sits on this spectrum.

40–41 D-Index: 289 scientists 42–43 D-Index: 612 scientists 44–45 D-Index: 808 scientists 46–47 D-Index: 776 scientists 48–49 D-Index: 835 scientists 50–51 D-Index: 861 scientists 52–53 D-Index: 872 scientists 54–55 D-Index: 933 scientists 56–57 D-Index: 1,051 scientists 58–59 D-Index: 930 scientists 60–61 D-Index: 882 scientists 62–63 D-Index: 834 scientists 64–65 D-Index: 731 scientists 66–67 D-Index: 776 scientists 68–69 D-Index: 683 scientists 70–71 D-Index: 647 scientists 72–73 D-Index: 561 scientists 74–75 D-Index: 501 scientists 76–77 D-Index: 437 scientists 78–79 D-Index: 388 scientists 80–81 D-Index: 354 scientists 82–83 D-Index: 292 scientists 84–85 D-Index: 275 scientists 86–87 D-Index: 254 scientists 88–89 D-Index: 235 scientists 90–91 D-Index: 185 scientists 92–93 D-Index: 192 scientists 94–95 D-Index: 155 scientists 96–97 D-Index: 163 scientists 98–99 D-Index: 125 scientists 100–101 D-Index: 105 scientists 102–103 D-Index: 105 scientists 104–105 D-Index: 112 scientists 106–107 D-Index: 88 scientists 108–109 D-Index: 68 scientists 110–111 D-Index: 69 scientists 112–113 D-Index: 65 scientists 114–115 D-Index: 79 scientists 116–117 D-Index: 61 scientists 118–119 D-Index: 44 scientists 120–121 D-Index: 37 scientists 122–123 D-Index: 40 scientists 124–125 D-Index: 33 scientists 126–127 D-Index: 26 scientists 128–129 D-Index: 34 scientists 130–131 D-Index: 35 scientists 132–133 D-Index: 25 scientists 134–135 D-Index: 27 scientists 136–137 D-Index: 17 scientists 138–139 D-Index: 16 scientists 140–141 D-Index: 20 scientists 142–143 D-Index: 20 scientists 144–145 D-Index: 15 scientists 146–147 D-Index: 9 scientists 148–149 D-Index: 9 scientists 150–151 D-Index: 16 scientists 152–153 D-Index: 11 scientists 154–155 D-Index: 9 scientists 156–157 D-Index: 3 scientists 158 D-Index: 3 scientists 159+ D-Index: 98 scientists
40 D-Index 159+

This scientist: 45 D-Index — 10th percentile

10% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 159 D-Index or more.

Overview

Brian D. Palmer is affiliated with the University of Auckland in New Zealand. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with specific focus areas in Molecular Biology, Infectious Diseases, Physiology, Pharmacology, and Biological Psychiatry.

The scientist's work addresses major topics including Tuberculosis Research and Epidemiology, Cancer therapeutics and mechanisms, Biochemical and Molecular Research, Tryptophan and brain disorders, ATP Synthase and ATPases Research, Synthesis and biological activity, and Circadian rhythm and melatonin.

Frequent publication venues where Brian D. Palmer's research appears include Bioorganic & Medicinal Chemistry, Pharmaceuticals, Tetrahedron Letters, Frontiers in Neuroscience, and Molecules.

Key recent papers authored or co-authored by Brian D. Palmer are:

  • Synthesis and structure-activity relationships for tetrahydroisoquinoline-based inhibitors of Mycobacterium tuberculosis (2020, Bioorganic & Medicinal Chemistry)
  • Synthetic Studies to Help Elucidate the Metabolism of the Preclinical Candidate TBAJ-876-A Less Toxic and More Potent Analogue of Bedaquiline (2020, Molecules)
  • Synthetic studies towards isomeric pyrazolopyrimidines as potential ATP synthesis inhibitors of Mycobacterium tuberculosis. Structural correction of reported N-(6-(2-(dimethylamino)ethoxy)-5-fluoropyridin-3-yl)-2-(4-fluorophenyl)-5-(trifluoromethyl)pyrazolo[1,5-α]pyrimidin-7-amine (2021, Tetrahedron Letters)
  • Synthesis and structure-activity relationships for a new class of tetrahydronaphthalene amide inhibitors of Mycobacterium tuberculosis (2021, European Journal of Medicinal Chemistry)
  • Parallel discovery of selective and dual inhibitors of tryptophan dioxygenases IDO1 and TDO2 with a newly-modified enzymatic assay (2021, Bioorganic & Medicinal Chemistry)

Their frequent co-authors include Hamish S. Sutherland, Peter J. Choi, Christopher B. Cooper, William A. Denny, and Scott G. Franzblau.

Best Publications

  • Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review.

    Manju Kanamala;William R. Wilson;Mimi Yang;Brian D. Palmer

  • Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.

    J. B. Smaill;B. D. Palmer;G. W. Rewcastle;W. A. Denny

  • Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards.

    David C. Ware;Brian D. Palmer;William R. Wilson;William A. Denny

  • Relationships Between Hydrophobicity, Reactivity, Accumulation And Peripheral Nerve Toxicity Of A Series Of Platinum Drugs

    D. Screnci;M.J. McKeage;P. Galettis;T.W. Hambley

  • Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor

    Gordon W. Rewcastle;Brian D. Palmer;Alexander J. Bridges;H. D. Hollis Showalter

  • Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor.

    Gordon W. Rewcastle;Brian D. Palmer;Andrew M. Thompson;Alexander J. Bridges

  • Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells

    Leslie A. Parsels;Meredith A. Morgan;Daria M. Tanska;Joshua D. Parsels

  • Tyrosine Kinase Inhibitors. 11. Soluble Analogues of Pyrrolo- and Pyrazoloquinazolines as Epidermal Growth Factor Receptor Inhibitors: Synthesis, Biological Evaluation, and Modeling of the Mode of Binding

    Brian D. Palmer;Susanne Trumpp-Kallmeyer;David W. Fry;James M. Nelson

  • Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N-bis(2-chloroethyl)anilines.

    Brian D. Palmer;William R. Wilson;Susan M. Pullen;William A. Denny

  • Synthesis and Structure−Activity Relationships of Aza- and Diazabiphenyl Analogues of the Antitubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)

    Iveta Kmentova;Hamish S. Sutherland;Brian D. Palmer;Adrian Blaser

  • Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).

    Brian D. Palmer;Andrew M. Thompson;Hamish S. Sutherland;Adrian Blaser

  • 4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitution.

    Brian D Palmer;Andrew M Thompson;R John Booth;Ellen M Dobrusin

  • Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase.

    G.M. Anlezark;R.G. Melton;R.F. Sherwood;W.R. Wilson

  • Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).

    Andrew M. Thompson;Adrian Blaser;Robert F. Anderson;Sujata S. Shinde

  • Potential antitumor agents. 54. Chromophore requirements for in vivo antitumor activity among the general class of linear tricyclic carboxamides

    Brian D. Palmer;Gordon W. Rewcastle;Graham J. Atwell;Bruce C. Baguley

  • Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells.

    Brian D. Palmer;William R. Wilson;Stephen Cliffe;William A. Denny

  • Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy

    Frank Friedlos;William A. Denny;Brian D. Palmer;Caroline J. Springer

  • DNA-directed alkylating agents. 5. Acridinecarboxamide derivatives of (1,2-diaminoethane)dichloroplatinum(II).

    Ho H. Lee;Brian D. Palmer;Bruce C. Baguley;Michael Chin

  • Structure-activity relationships for 2-anilino-6-phenylpyrido[2,3-d]pyrimidin-7(8H)-ones as inhibitors of the cellular checkpoint kinase Wee1.

    Brian D. Palmer;Jeff B. Smaill;Gordon W. Rewcastle;Ellen M. Dobrusin

  • Total synthesis of the ionophore antibiotic X-14547A (Indanomycin)

    Martin P. Edwards;Steven V. Ley;Simon G. Lister;Brian D. Palmer

  • 3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel.

    Hamish S. Sutherland;Amy S.T. Tong;Peter J. Choi;Adrian Blaser

Frequent Co-Authors

William A. Denny
William A. Denny University of Auckland
William R. Wilson
William R. Wilson University of Auckland
Bruce C. Baguley
Bruce C. Baguley University of Auckland
Scott G. Franzblau
Scott G. Franzblau University of Illinois at Chicago
David W. Fry
David W. Fry Pfizer (United States)
Edward N. Baker
Edward N. Baker University of Auckland
Colin J. Jackson
Colin J. Jackson Australian National University
Steven V. Ley
Steven V. Ley University of Cambridge
Jun Lu
Jun Lu Zhejiang University
Lynnette R. Ferguson
Lynnette R. Ferguson University of Auckland

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Chemistry in the USA opens doors to various interdisciplinary careers. Students interested in expanding their expertise often consider related fields like criminal justice, paralegal studies, and pharmaceutical sales. Understanding the associated costs and educational pathways can help make informed decisions.

For those curious about the financial commitment, learning how much is criminal justice school is a good starting point. This insight is particularly useful for individuals considering dual interests in science and law enforcement or regulatory affairs.

An alternative route is pursuing a criminal justice associate degree online, which offers flexibility and foundational knowledge, potentially complementing a chemistry background for careers in forensic science or legal compliance.

Additionally, paralegal roles related to chemical patents or environmental law can be lucrative. Understanding paralegal salary trends helps gauge the financial benefits of entering this field alongside chemistry expertise.

Lastly, a career as a pharmaceutical sales representative merges science and business skills. Prospective candidates should review pharma sales rep salary and career pathways to understand growth potential within the chemistry-related industry.

Best Scientists Citing Brian D. Palmer

Trending Scientists

Recently Published Articles